We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




UV Disinfecting Light Effective Against Resistant Superbugs

By HospiMedica International staff writers
Posted on 09 Aug 2019
Specialized ultraviolet (UV) disinfectant lighting products been shown to kill up to 99.9% of the deadly, multidrug resistant Candida auris fungus.

The Puro (Denver, CO, USA) Helo UV disinfectant lighting fixtures are designed to routinely disinfect a whole room from a fixed position, with broad spectrum UV light production that optimizes germ-killing efficiency. More...
The fixtures can be operated manually, or integrated into a healthcare facility building automation system (BAS). The Sentry series, based on the same technology, is available in several mobile configurations that can be moved from room to room, deployed on uneven surfaces, and even placed on desktops and surfaces. Both can kill 99.9% of bacteria, viruses, mold, and fungus from a distance of three meters, including C. auris fungus.

The Puro fixtures were designed using exclusive patents and technology acquired from Violet Defense, which includes high intensity germicidal UV emission in the UV-C, UV-B, UV-A, and violet blue wavelengths. UV-C (200-280 nm) most efficiently kills bacteria, viruses, mold, and fungi; the UV-B (280-320nm) wavelength demonstrates effectiveness against specific bacteria; and UV-A (320-400 nm) causes oxidation of proteins and lipids, leading to cell death. Broadband UV lamps have also been shown to inhibit microbial photo-reactivation.

“Puro was formed in part to introduce new technologies and innovations in the fight against Healthcare Associated Infections (HAIs) caused by drug resistant superbugs such as C. auris,” said Jim Colantoni, co-founder and General Manager of Puro. “Our Helo and Sentry UV disinfecting products are an effective, new tool to fight HAIs, including this multidrug resistant fungus and reduce the suffering, loss of life, and treatment burden.”

C. auris fungus, a species of ascomycetous fungus that grows as a yeast, was first identified in Japan in 2009. It is of great concern due to multidrug resistance, difficulty to identify with standard laboratory methods, and previous outbreaks in healthcare settings. According to the U.S. Centers for Disease Control and Prevention, C. auris is able to survive on surfaces for weeks at a time, colonizing on high-touch areas such as hospital beds, windowsills and mobile medical equipment positioned in the room.

Related Links:
Puro


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
MRI System
nanoScan MRI 3T/7T
Endoscopy Display
E190
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.